TrialThe oncologist2019

Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.

Consuelo Buttigliero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.